1. Home
  2. MAN vs VRDN Comparison

MAN vs VRDN Comparison

Compare MAN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ManpowerGroup

MAN

ManpowerGroup

HOLD

Current Price

$30.40

Market Cap

1.4B

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$13.74

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAN
VRDN
Founded
1948
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
MAN
VRDN
Price
$30.40
$13.74
Analyst Decision
Hold
Strong Buy
Analyst Count
6
14
Target Price
$35.67
$35.46
AVG Volume (30 Days)
1.2M
3.5M
Earning Date
04-16-2026
05-07-2026
Dividend Yield
4.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,957,100,000.00
$5,706,000.00
Revenue This Year
$5.12
$13.73
Revenue Next Year
$3.42
$279.00
P/E Ratio
N/A
N/A
Revenue Growth
0.58
N/A
52 Week Low
$25.15
$11.76
52 Week High
$47.34
$34.29

Technical Indicators

Market Signals
Indicator
MAN
VRDN
Relative Strength Index (RSI) 54.35 23.57
Support Level $28.76 $13.33
Resistance Level $30.40 $18.95
Average True Range (ATR) 1.91 0.66
MACD 0.02 0.29
Stochastic Oscillator 60.43 7.67

Price Performance

Historical Comparison
MAN
VRDN

About MAN ManpowerGroup

ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: